Raphael Pharmaceutical Inc. (RAPH)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development expenses | 141 | |||
| General and administrative expenses | 174 | |||
| Operating loss | -315 | |||
| Total financial expense | -7 | |||
| Net loss | -322 | |||
| Basic net loss per share (in dollars per share) | 0.02 | |||
| Diluted net loss per share (in dollars per share) | 0.02 | |||
| Weighted average number of shares of common stock used in computing basic net loss per share (in shares) | 19,626,418 | |||
| Weighted average number of shares of common stock used in computing diluted net loss per share (in shares) | 19,626,418 | |||